N,N‐dimethyltryptamine and Amazonian ayahuasca plant medicine
Human Psychopharmacology: Clinical and Experimental · 2022-05 · 37 (3)
DOI: 10.1002/hup.2835 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Human Psychopharmacology: Clinical and Experimental, online erschienen am 17.02.2022. Verfasst von Edward James und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK. Hauptthemen laut MEDLINE: Banisteriopsis, Behavior, Addictive. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 331 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
Reports have indicated possible uses of ayahuasca for the treatment of conditions including depression, addictions, post‐traumatic stress disorder, anxiety and specific psychoneuroendocrine immune system pathologies. The article assesses potential ayahuasca and N,N‐dimethyltryptamine (DMT) integration with contemporary healthcare. The review also seeks to provide a summary of selected literature regarding the mechanisms of action of DMT and ayahuasca; and assess to what extent the state of research can explain reports of unusual phenomenology.
Design
A narrative review.
Results
Compounds in ayahuasca have been found to bind to serotonergic receptors, glutaminergic receptors, sigma‐1 receptors, trace amine‐associated receptors, and modulate BDNF expression and the dopaminergic system. Subjective effects are associated with increased delta and theta oscillations in amygdala and hippocampal regions, decreased alpha wave activity in the default mode network, and stimulations of vision‐related brain regions particularly in the visual association cortex. Both biological processes and field of consciousness models have been proposed to explain subjective effects of DMT and ayahuasca, however, the evidence supporting the proposed models is not sufficient to make confident conclusions. Ayahuasca plant medicine and DMT represent potentially novel treatment modalities.
Conclusions
Further research is required to clarify the mechanisms of action and develop treatments which can be made available to the general public. Integration between healthcare research institutions and reputable practitioners in the Amazon is recommended.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK.
- Department of Consciousness Research, DIWISS, Roth, Germany.
- Centre for Neuropsychopharmacology, Division of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.
ORCID-Profile: Edward James
Zitieren
APA
James, E., Keppler, J., L Robertshaw, T., & Sessa, B. (2022). N,N‐dimethyltryptamine and Amazonian ayahuasca plant medicine. Human Psychopharmacology: Clinical and Experimental, 37(3). https://doi.org/10.1002/hup.2835
Vancouver
James E, Keppler J, L Robertshaw T, Sessa B. N,N‐dimethyltryptamine and Amazonian ayahuasca plant medicine. Human Psychopharmacology: Clinical and Experimental. 2022;37(3). doi:10.1002/hup.2835
BibTeX
@article{James2022,
author = {James, Edward and Keppler, Joachim and L Robertshaw, Thomas and Sessa, Ben},
title = {N,N‐dimethyltryptamine and Amazonian ayahuasca plant medicine},
journal = {Human Psychopharmacology: Clinical and Experimental},
year = {2022},
volume = {37},
number = {3},
doi = {10.1002/hup.2835}
}
EUVIMED